CureVax and Novavax Rally as CDC Reports Rising U.S. COVID-19, RSV, and Influenza Cases

The Centers for Disease Control and Prevention (CDC) has reported a surge in COVID-19, RSV, and influenza cases across the United States, leading to a rally in the shares of vaccine developers CureVax and Novavax. As the demand for vaccines increases, investors are showing renewed interest in these companies, driving up their stock prices.